Cargando…
Synergism of FAK and ROS1 inhibitors in the treatment of CDH1-deficient cancers mediated by FAK-YAP signaling
CDH1 deficiency is common in diffuse gastric cancer and triple negative breast cancer patients, both of which still lack effective therapeutics. ROS1 inhibition results in synthetic lethality in CDH1-deficient cancers, but often leads to adaptive resistance. Here, we demonstrate that upregulation of...
Autores principales: | Gao, Jiaming, Yao, Yunying, Liu, Chenxuan, Xie, Xi, Li, Donghe, Liu, Ping, Wang, Zaiqi, Zhang, Baoyuan, Ren, Ruibao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266074/ https://www.ncbi.nlm.nih.gov/pubmed/37324948 http://dx.doi.org/10.7150/ijbs.81918 |
Ejemplares similares
-
Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling
por: Zhang, Baoyuan, et al.
Publicado: (2021) -
A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia
por: Wang, Peihong, et al.
Publicado: (2021) -
Backtracking on FAK
por: Leslie, Mitch
Publicado: (2008) -
FAK monitoring
por: Metzmacher, K D
Publicado: (1974) -
Exploring the influence of cytosolic and membrane FAK activation on YAP/TAZ nuclear translocation
por: Eroumé, Kerbaï Saïd, et al.
Publicado: (2021)